Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results
Data Presented at ASCO Support Broad Potential of Mirvetuximab Soravtansine in Ovarian Cancer Sanofi and Debiopharm Transactions Strengthen Cash Position Conference Call to be Held at 8:00am ET Today WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc .
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 28, 2017 , to discuss its second quarter
View HTML
Toggle Summary ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia
Data demonstrate favorable safety profile with repeat dosing and no dose-limiting toxicities Dose-dependent biological and anti-leukemia activity observed WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the
View HTML